Cargando…

Radiomics Assessment of the Tumor Immune Microenvironment to Predict Outcomes in Breast Cancer

BACKGROUND: The immune microenvironment of tumors provides information on prognosis and prediction. A prior validation of the immunoscore for breast cancer (IS(BC)) was made on the basis of a systematic assessment of immune landscapes extrapolated from a large number of neoplastic transcripts. Our g...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Xiaorui, Cao, Wuteng, Wu, Lei, Liang, Changhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8761791/
https://www.ncbi.nlm.nih.gov/pubmed/35046937
http://dx.doi.org/10.3389/fimmu.2021.773581
_version_ 1784633609873784832
author Han, Xiaorui
Cao, Wuteng
Wu, Lei
Liang, Changhong
author_facet Han, Xiaorui
Cao, Wuteng
Wu, Lei
Liang, Changhong
author_sort Han, Xiaorui
collection PubMed
description BACKGROUND: The immune microenvironment of tumors provides information on prognosis and prediction. A prior validation of the immunoscore for breast cancer (IS(BC)) was made on the basis of a systematic assessment of immune landscapes extrapolated from a large number of neoplastic transcripts. Our goal was to develop a non-invasive radiomics-based IS(BC) predictive factor. METHODS: Immunocell fractions of 22 different categories were evaluated using CIBERSORT on the basis of a large, open breast cancer cohort derived from comprehensive information on gene expression. The IS(BC) was constructed using the LASSO Cox regression model derived from the Immunocell type scores, with 479 quantified features in the intratumoral and peritumoral regions as observed from DCE-MRI. A radiomics signature [radiomics ImmunoScore (RIS)] was developed for the prediction of IS(BC) using a random forest machine-learning algorithm, and we further evaluated its relationship with prognosis. RESULTS: An IS(BC) consisting of seven different immune cells was established through the use of a LASSO model. Multivariate analyses showed that the IS(BC) was an independent risk factor in prognosis (HR=2.42, with a 95% CI of 1.49–3.93; P<0.01). A radiomic signature of 21 features of the IS(BC) was then exploited and validated (the areas under the curve [AUC] were 0.899 and 0.815). We uncovered statistical associations between the RIS signature with recurrence-free and overall survival rates (both P<0.05). CONCLUSIONS: The RIS is a valuable instrument with which to assess the immunoscore, and offers important implications for the prognosis of breast cancer.
format Online
Article
Text
id pubmed-8761791
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-87617912022-01-18 Radiomics Assessment of the Tumor Immune Microenvironment to Predict Outcomes in Breast Cancer Han, Xiaorui Cao, Wuteng Wu, Lei Liang, Changhong Front Immunol Immunology BACKGROUND: The immune microenvironment of tumors provides information on prognosis and prediction. A prior validation of the immunoscore for breast cancer (IS(BC)) was made on the basis of a systematic assessment of immune landscapes extrapolated from a large number of neoplastic transcripts. Our goal was to develop a non-invasive radiomics-based IS(BC) predictive factor. METHODS: Immunocell fractions of 22 different categories were evaluated using CIBERSORT on the basis of a large, open breast cancer cohort derived from comprehensive information on gene expression. The IS(BC) was constructed using the LASSO Cox regression model derived from the Immunocell type scores, with 479 quantified features in the intratumoral and peritumoral regions as observed from DCE-MRI. A radiomics signature [radiomics ImmunoScore (RIS)] was developed for the prediction of IS(BC) using a random forest machine-learning algorithm, and we further evaluated its relationship with prognosis. RESULTS: An IS(BC) consisting of seven different immune cells was established through the use of a LASSO model. Multivariate analyses showed that the IS(BC) was an independent risk factor in prognosis (HR=2.42, with a 95% CI of 1.49–3.93; P<0.01). A radiomic signature of 21 features of the IS(BC) was then exploited and validated (the areas under the curve [AUC] were 0.899 and 0.815). We uncovered statistical associations between the RIS signature with recurrence-free and overall survival rates (both P<0.05). CONCLUSIONS: The RIS is a valuable instrument with which to assess the immunoscore, and offers important implications for the prognosis of breast cancer. Frontiers Media S.A. 2022-01-03 /pmc/articles/PMC8761791/ /pubmed/35046937 http://dx.doi.org/10.3389/fimmu.2021.773581 Text en Copyright © 2022 Han, Cao, Wu and Liang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Han, Xiaorui
Cao, Wuteng
Wu, Lei
Liang, Changhong
Radiomics Assessment of the Tumor Immune Microenvironment to Predict Outcomes in Breast Cancer
title Radiomics Assessment of the Tumor Immune Microenvironment to Predict Outcomes in Breast Cancer
title_full Radiomics Assessment of the Tumor Immune Microenvironment to Predict Outcomes in Breast Cancer
title_fullStr Radiomics Assessment of the Tumor Immune Microenvironment to Predict Outcomes in Breast Cancer
title_full_unstemmed Radiomics Assessment of the Tumor Immune Microenvironment to Predict Outcomes in Breast Cancer
title_short Radiomics Assessment of the Tumor Immune Microenvironment to Predict Outcomes in Breast Cancer
title_sort radiomics assessment of the tumor immune microenvironment to predict outcomes in breast cancer
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8761791/
https://www.ncbi.nlm.nih.gov/pubmed/35046937
http://dx.doi.org/10.3389/fimmu.2021.773581
work_keys_str_mv AT hanxiaorui radiomicsassessmentofthetumorimmunemicroenvironmenttopredictoutcomesinbreastcancer
AT caowuteng radiomicsassessmentofthetumorimmunemicroenvironmenttopredictoutcomesinbreastcancer
AT wulei radiomicsassessmentofthetumorimmunemicroenvironmenttopredictoutcomesinbreastcancer
AT liangchanghong radiomicsassessmentofthetumorimmunemicroenvironmenttopredictoutcomesinbreastcancer